{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "585960b1",
   "metadata": {},
   "outputs": [],
   "source": [
    "from textwrap import wrap\n",
    "import pandas as pd\n",
    "import requests\n",
    "import json\n",
    "from pandas import json_normalize # tranform JSON file into a pandas dataframe\n",
    "import time\n",
    "import re\n",
    "\n",
    "pd.set_option('display.max_colwidth', 100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "17e67ed0",
   "metadata": {},
   "outputs": [],
   "source": [
    "def build_url_from_query(query):\n",
    "    \n",
    "    query_tokenized = query.split()\n",
    "    \n",
    "    field_values = ['NCTId', 'LeadSponsorName', 'BriefTitle', 'Condition', 'Phase', 'StudyType',\n",
    "                    'EnrollmentCount', 'StartDate', 'PrimaryCompletionDate', 'EligibilityCriteria', 'InterventionName', \n",
    "                    'ArmGroupInterventionName', 'ArmGroupDescription', 'InterventionArmGroupLabel', 'OutcomeMeasureType', 'OutcomeMeasureTitle',\n",
    "                    'OutcomeMeasureDescription', 'OutcomeMeasureTimeFrame', 'OutcomeMeasurementValue', 'OutcomeMeasureUnitOfMeasure']\n",
    "    \n",
    "    max_rank = 1000             # max number of items returned by the API query (max for the clinicaltrials.gov API is 1000)\n",
    "    \n",
    "    \n",
    "    url = 'https://clinicaltrials.gov/api/query/study_fields?expr='\n",
    "    \n",
    "    for i, word in enumerate(query_tokenized):              # build query URL by adding all search terms and field values to the query URL, following the appropriate format\n",
    "        if i == 0:\n",
    "            url = url + word\n",
    "        else:\n",
    "            url = url + '+' + word\n",
    "        \n",
    "    url = url + '&fields='\n",
    "    \n",
    "    for i, word in enumerate(field_values):\n",
    "        if i == 0:\n",
    "            url = url + word\n",
    "        else:\n",
    "            url = url + '%2C' + word\n",
    "    \n",
    "    url = url + '&min_rnk=1&max_rnk=' + str(max_rank) + '&fmt=json' \n",
    "    url = url.strip()\n",
    "    \n",
    "    # print('\\n\\nQuerying up to 1,000 trials from clinicaltrials.gov with the following url...\\n\\n'+url+'\\n\\n')\n",
    "    \n",
    "    return url"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "ddeaf095",
   "metadata": {},
   "outputs": [],
   "source": [
    "def build_study_table(url):\n",
    "        \n",
    "    ## convert the clinicaltrials.gov JSON response to a pandas dataframe\n",
    "    \n",
    "    result = requests.get(url).json()\n",
    "    \n",
    "    # loop through the list and identify ONLY studies with outcome measures reported \n",
    "    # result_list = [result for result in result['StudyFieldsResponse']['StudyFields'] if result['OutcomeMeasureType']]     \n",
    "    # result_list = [result for result in result['StudyFieldsResponse']['StudyFields']]\n",
    "    \n",
    "    result_list = [result for result in result['StudyFieldsResponse']['StudyFields'] if result['StudyType'][0] == 'Interventional']\n",
    "    \n",
    "    \n",
    "    df_master = json_normalize(result_list[0])      # initialize dataframe using JSON result\n",
    "\n",
    "    df_master = clean_columns(df_master)\n",
    "\n",
    "    try:\n",
    "        for study in result_list[1:]:        # concatenate each study to the dataframe to generate master dataframe\n",
    "            df = json_normalize(study)\n",
    "            df = clean_columns(df)\n",
    "            df_master = pd.concat([df_master, df], axis=0, ignore_index=True)\n",
    "    except:\n",
    "        print(\"There was an error!\")\n",
    "    \n",
    "#     df_master = df_master[(df_master['Phase'].str.match('.*3.*')) | (df_master['Phase'].str.match('.*2.*'))]\n",
    "#     df_master = df_master[df_master['Phase'].str.match('.*3.*')].drop('Rank', 1).reset_index().drop('index', 1)\n",
    "    df_master = df_master[df_master['Phase'].str.match('.*3.*')]\n",
    "    \n",
    "    return df_master"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "ad40ed71",
   "metadata": {},
   "outputs": [],
   "source": [
    "def clean_columns(df_master):      # this is a single-row dataframe\n",
    "    for col in df_master.columns[1:]:    \n",
    "        if len(df_master[col][0]) == 0:\n",
    "            df_master[col] = 'Unreported'\n",
    "        elif (len(df_master[col][0]) == 1) and (not re.search('Outcome.*', col)):\n",
    "            df_master[col] = df_master[col][0]\n",
    "        elif (len(df_master[col][0]) > 1) and (not re.search('Outcome.*', col)):\n",
    "            df_master[col] = ', '.join(df_master[col][0])\n",
    "    \n",
    "    return df_master\n",
    "\n",
    "# is it an outcome column?\n",
    "# is length greater than 0?\n",
    "\n",
    "# scenarios\n",
    "# is any column, 0 length - confirmed\n",
    "# is outcome column, any length - confirmed\n",
    "# is not outcome column, 1 length - confirmed\n",
    "# is not outcome column, >1 length - confirmed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "ee6bc704",
   "metadata": {},
   "outputs": [],
   "source": [
    "def map_measure_values(df_master):      # this is a single-row dataframe\n",
    "    if df_master\n",
    "    num_of_outcomes = len(df_master['OutcomeMeasureType'][0])\n",
    "    temp_list = []\n",
    "    try:                            \n",
    "        measures_per_outcome = len(df_master['OutcomeMeasurementValue'][0])//len(df_master['OutcomeMeasureTitle'][0])\n",
    "    except:\n",
    "        measures_per_outcome = 1\n",
    "    \n",
    "    beginning = 0\n",
    "    increment = measures_per_outcome               # maps correct number of outcome measures reported in the study, as multiple performance values may pertain to each endpoint (i.e. value for each intervention arm + placebo)\n",
    "    try:\n",
    "        for i in range(num_of_outcomes):\n",
    "            try:\n",
    "                temp_list.append([df_master['OutcomeMeasurementValue'][0][beginning:beginning+increment]])\n",
    "                beginning += increment\n",
    "            except:\n",
    "                print('Errors!')\n",
    "        df_master['OutcomeMeasurementValue'] = temp_list\n",
    "    except:\n",
    "        print('Errors!')\n",
    "    \n",
    "    return df_master"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "ea84e562",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Enter search query: \n",
      "eosinophilic asthma\n",
      "Time to build url: 0.0 seconds\n",
      "https://clinicaltrials.gov/api/query/study_fields?expr=eosinophilic+asthma&fields=NCTId%2CLeadSponsorName%2CBriefTitle%2CCondition%2CPhase%2CStudyType%2CEnrollmentCount%2CStartDate%2CPrimaryCompletionDate%2CEligibilityCriteria%2CInterventionName%2CArmGroupInterventionName%2CArmGroupDescription%2CInterventionArmGroupLabel%2COutcomeMeasureType%2COutcomeMeasureTitle%2COutcomeMeasureDescription%2COutcomeMeasureTimeFrame%2COutcomeMeasurementValue%2COutcomeMeasureUnitOfMeasure&min_rnk=1&max_rnk=1000&fmt=json\n"
     ]
    }
   ],
   "source": [
    "query_term = input(\"Enter search query: \\n\")\n",
    "start_time = time.process_time()\n",
    "url = build_url_from_query(query_term)\n",
    "print(f\"Time to build url: {time.process_time()-start_time} seconds\")\n",
    "print(url)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "59c41e1c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Time to build table: 0.6875 seconds.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\tenoc\\AppData\\Local\\Temp/ipykernel_34588/1657706757.py:27: FutureWarning: In a future version of pandas all arguments of DataFrame.drop except for the argument 'labels' will be keyword-only\n",
      "  df_master = df_master[df_master['Phase'].str.match('.*3.*')].drop('Rank', 1).reset_index().drop('index', 1)\n"
     ]
    }
   ],
   "source": [
    "start_time = time.process_time()\n",
    "study_table = build_study_table(url)\n",
    "print(f\"Time to build table: {time.process_time()-start_time} seconds.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "id": "78573ef7",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCTId</th>\n",
       "      <th>LeadSponsorName</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Phase</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>EnrollmentCount</th>\n",
       "      <th>StartDate</th>\n",
       "      <th>PrimaryCompletionDate</th>\n",
       "      <th>EligibilityCriteria</th>\n",
       "      <th>InterventionName</th>\n",
       "      <th>ArmGroupInterventionName</th>\n",
       "      <th>ArmGroupDescription</th>\n",
       "      <th>InterventionArmGroupLabel</th>\n",
       "      <th>OutcomeMeasureType</th>\n",
       "      <th>OutcomeMeasureTitle</th>\n",
       "      <th>OutcomeMeasureDescription</th>\n",
       "      <th>OutcomeMeasureTimeFrame</th>\n",
       "      <th>OutcomeMeasurementValue</th>\n",
       "      <th>OutcomeMeasureUnitOfMeasure</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT01285323</td>\n",
       "      <td>Teva Branded Pharmaceutical Products R&amp;D, Inc.</td>\n",
       "      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma</td>\n",
       "      <td>Eosinophilic Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>464</td>\n",
       "      <td>March 2011</td>\n",
       "      <td>April 2014</td>\n",
       "      <td>Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...</td>\n",
       "      <td>Reslizumab, Placebo</td>\n",
       "      <td>Drug: Placebo, Drug: Reslizumab</td>\n",
       "      <td>Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Resl...</td>\n",
       "      <td>Reslizumab 3.0 mg/kg, Placebo</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n",
       "      <td>[Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...</td>\n",
       "      <td>[An exacerbation event was considered a CAE if the patient met either or both of the criteria li...</td>\n",
       "      <td>[Day 1 to Month 12, Day 1 (baseline, pre-dose), Week 16, Day 1 (baseline, pre-dose), Weeks 4, 8,...</td>\n",
       "      <td>[2.115, 0.859, 0.122, 0.223, 0.094, 0.187, 0.777, 0.987, -0.660, -0.857, NA, NA, 0.080, 0.115, -...</td>\n",
       "      <td>[CAEs in 52 weeks, liters, liters, units on a scale, units on a scale, weeks, units on a scale, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01287039</td>\n",
       "      <td>Teva Branded Pharmaceutical Products R&amp;D, Inc.</td>\n",
       "      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...</td>\n",
       "      <td>Eosinophilic Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>489</td>\n",
       "      <td>April 2011</td>\n",
       "      <td>December 2013</td>\n",
       "      <td>Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...</td>\n",
       "      <td>Reslizumab, Placebo</td>\n",
       "      <td>Drug: Placebo, Drug: Reslizumab</td>\n",
       "      <td>Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Resl...</td>\n",
       "      <td>Reslizumab 3.0 mg/kg, Placebo</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n",
       "      <td>[Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...</td>\n",
       "      <td>[An exacerbation event was considered a CAE if the patient met either or both of the criteria li...</td>\n",
       "      <td>[Day 1 to Week 52, Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose)...</td>\n",
       "      <td>[1.804, 0.904, 0.110, 0.248, 0.695, 0.933, -0.676, -0.941, 34.9, NA, 0.109, 0.167, -0.36, -0.64,...</td>\n",
       "      <td>[CAEs in 52 weeks, liters, units on a scale, units on a scale, weeks, units on a scale, puffs/da...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01270464</td>\n",
       "      <td>Teva Branded Pharmaceutical Products R&amp;D, Inc.</td>\n",
       "      <td>A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...</td>\n",
       "      <td>Eosinophilic Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>315</td>\n",
       "      <td>February 2011</td>\n",
       "      <td>September 2013</td>\n",
       "      <td>Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...</td>\n",
       "      <td>Reslizumab, Placebo</td>\n",
       "      <td>Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab</td>\n",
       "      <td>Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses., 0.3 mg/kg, ...</td>\n",
       "      <td>Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n",
       "      <td>[Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed M...</td>\n",
       "      <td>[FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fr...</td>\n",
       "      <td>[Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose), Weeks 4, 8, 12, ...</td>\n",
       "      <td>[0.126, 0.242, 0.286, 0.172, 0.220, 0.301, -0.145, -0.114, 0.089, 0.8, 4.9, 7.5, 0.8, 5.5, 6.7, ...</td>\n",
       "      <td>[liters, liters, liters/second, percentage of predicted FEV1, units on a scale, units on a scale...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01290887</td>\n",
       "      <td>Teva Branded Pharmaceutical Products R&amp;D, Inc.</td>\n",
       "      <td>Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/k...</td>\n",
       "      <td>Eosinophilic Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>1052</td>\n",
       "      <td>June 2011</td>\n",
       "      <td>January 2015</td>\n",
       "      <td>Inclusion Criteria:\\n\\nWritten informed consent is obtained.\\nPatient must have completed treatm...</td>\n",
       "      <td>Reslizumab</td>\n",
       "      <td>Drug: Reslizumab</td>\n",
       "      <td>Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.</td>\n",
       "      <td>Reslizumab 3.0 mg/kg</td>\n",
       "      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Primary, Secondary, Se...</td>\n",
       "      <td>[Participants With Treatment-Emergent Adverse Events, Participants With Treatment-Emergent Poten...</td>\n",
       "      <td>[An adverse event was defined in the protocol as any untoward medical occurrence that develops o...</td>\n",
       "      <td>[Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observa...</td>\n",
       "      <td>[359, 385, 744, 31, 47, 78, 49, 41, 90, 6, 12, 18, 33, 45, 78, 1, 2, 3, 344, 367, 711, 78, 82, 1...</td>\n",
       "      <td>[participants, participants, liters, percentage of predicted FEV1, liters, liters/second, # puff...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT02594332</td>\n",
       "      <td>Johannes Gutenberg University Mainz</td>\n",
       "      <td>Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic As...</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>29</td>\n",
       "      <td>November 17, 2015</td>\n",
       "      <td>May 22, 2017</td>\n",
       "      <td>Inclusion Criteria:\\n\\nPatients must be able to give written informed consent prior to participa...</td>\n",
       "      <td>Mepolizumab, Placebo</td>\n",
       "      <td>Drug: Mepolizumab, Drug: Placebo</td>\n",
       "      <td>100 mg SC every 4 weeks for 13 injections, Amount of Placebo corresponding to mepolizumab dose S...</td>\n",
       "      <td>Mepolizumab, Placebo</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT02555371</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>306</td>\n",
       "      <td>January 7, 2016</td>\n",
       "      <td>July 24, 2019</td>\n",
       "      <td>Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...</td>\n",
       "      <td>Mepolizumab 100mg, Placebo</td>\n",
       "      <td>Biological: Mepolizumab 100mg, Biological: Mepolizumab 100mg, Drug: Placebo</td>\n",
       "      <td>There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to...</td>\n",
       "      <td>Arm Mepolizumab 100 mg, Arm Placebo, Arm Placebo</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary]</td>\n",
       "      <td>[Percentage of Participants With First Clinically Significant Exacerbation in Part C, Ratio to B...</td>\n",
       "      <td>[Clinically significant exacerbation was defined as worsening of asthma which requires use of sy...</td>\n",
       "      <td>[Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 an...</td>\n",
       "      <td>[31.8, 20.2, 49.3, 32.3, 56.0, 40.3, 60.7, 47.1, 6.03, 1.16, 6.58, 1.03, 6.48, 1.20, 6.17, 1.00,...</td>\n",
       "      <td>[Percentage of participants, Ratio, Percentage of participants, Percentage of participants]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT02281318</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinoph...</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>556</td>\n",
       "      <td>December 11, 2014</td>\n",
       "      <td>June 10, 2016</td>\n",
       "      <td>Inclusion Criteria:\\n\\nAge: At least 12 years of age at the time of signing the informed consent...</td>\n",
       "      <td>Mepolizumab, Placebo, SOC</td>\n",
       "      <td>Biological: Mepolizumab, Drug: SOC, Drug: Placebo, Drug: SOC</td>\n",
       "      <td>Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh eve...</td>\n",
       "      <td>Mepolizumab SC, Placebo SC, Mepolizumab SC, Placebo SC</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary]</td>\n",
       "      <td>[Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 2...</td>\n",
       "      <td>[SGRQ consisted of 50 questions (scored from 0 to 100 where 0 indicates best and 100 indicates w...</td>\n",
       "      <td>[Baseline and Week 24, Baseline and Week 24, Baseline (Visit 2-latest pre-dose assessment) and W...</td>\n",
       "      <td>[-7.9, -15.6, 56, 176, 55, 73, -0.40, -0.80]</td>\n",
       "      <td>[Scores on a scale, Milliliters (mL), Percentage of participants, Scores on a scale]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT04305405</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma</td>\n",
       "      <td>Severe Uncontrolled Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>30</td>\n",
       "      <td>November 21, 2019</td>\n",
       "      <td>October 31, 2022</td>\n",
       "      <td>Inclusion Criteria:\\n\\nPatients are eligible to be included in the study only if all of the foll...</td>\n",
       "      <td>Benralizumab</td>\n",
       "      <td>Drug: Benralizumab, Drug: Benralizumab</td>\n",
       "      <td>Below 35 kilos, Greater than/equal to 35 kilos</td>\n",
       "      <td>Dose 1, Dose 2</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT03052725</td>\n",
       "      <td>Teva Branded Pharmaceutical Products R&amp;D, Inc.</td>\n",
       "      <td>A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma</td>\n",
       "      <td>Eosinophils, Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>391</td>\n",
       "      <td>March 10, 2017</td>\n",
       "      <td>February 22, 2018</td>\n",
       "      <td>Inclusion Criteria:\\n\\n• Patient with eosinophilic asthma who completed the treatment period of ...</td>\n",
       "      <td>reslizumab</td>\n",
       "      <td>Drug: reslizumab</td>\n",
       "      <td>Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or uppe...</td>\n",
       "      <td>reslizumab 110 mg</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n",
       "      <td>[Participants With Treatment-Emergent Adverse Events (TEAEs), Participants With Potentially Clin...</td>\n",
       "      <td>[An adverse event is any untoward medical occurrence, regardless of whether it has a causal rela...</td>\n",
       "      <td>[Day 1 to up to Day 269; for participants who discontinued early for reasons other than study te...</td>\n",
       "      <td>[102, 114, 7, 6, 5, 11, 0, 0, 2, 0, 0, 0, 8, 5, 1, 0, 4, 2, 2, 0, 0, 1, 2, 0, 1, 1, 0, 1, 12, 10...</td>\n",
       "      <td>[Participants, Participants, Participants, Participants, Participants, CAEs / year, CAEs / year,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT02559791</td>\n",
       "      <td>McMaster University</td>\n",
       "      <td>Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma</td>\n",
       "      <td>Severe Persistent Asthma, Eosinophilic Bronchitis</td>\n",
       "      <td>Phase 2, Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>10</td>\n",
       "      <td>October 2015</td>\n",
       "      <td>April 2017</td>\n",
       "      <td>Inclusion Criteria:\\n\\nInformed consent Prior to the beginning of the study, patients must be wi...</td>\n",
       "      <td>Reslizumab, Placebo</td>\n",
       "      <td>Biological: Reslizumab, Drug: Placebo</td>\n",
       "      <td>All study participants will receive 2 monthly doses of placebo followed by 4 monthly doses of IV...</td>\n",
       "      <td>Study participants, Study participants</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NCT04049175</td>\n",
       "      <td>Chiesi Farmaceutici S.p.A.</td>\n",
       "      <td>Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma</td>\n",
       "      <td>Asthma; Eosinophilic</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>810</td>\n",
       "      <td>August 28, 2019</td>\n",
       "      <td>October 19, 2020</td>\n",
       "      <td>Inclusion Criteria:\\n\\nMale or female subjects aged ≥12 years and ≤75 years with a diagnosis of ...</td>\n",
       "      <td>Treatment A, Treatment B, Treatment C, Treatment D</td>\n",
       "      <td>Drug: Treatment A, Drug: Treatment B, Drug: Treatment C, Drug: Treatment D</td>\n",
       "      <td>Administration of CHF 6532 Dose #1, Administration of CHF 6532 Dose #2, Administration of CHF 65...</td>\n",
       "      <td>Treatment A, Treatment B, Treatment C, Treatment D</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>NCT03470311</td>\n",
       "      <td>McMaster University</td>\n",
       "      <td>Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies</td>\n",
       "      <td>Severe Prednisone Dependent Eosinophilic Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>20</td>\n",
       "      <td>April 26, 2018</td>\n",
       "      <td>April 2022</td>\n",
       "      <td>Inclusion Criteria:\\n\\nInformed consent Prior to the beginning of the study, patients must be wi...</td>\n",
       "      <td>Benralizumab, Placebo</td>\n",
       "      <td>Biological: Benralizumab, Biological: Placebo</td>\n",
       "      <td>Benralizumab 30mg in 1mL subcutaneously, Matched placebo (1mL) to active Benralizumab subcutaneo...</td>\n",
       "      <td>Benralizumab, Placebo</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>NCT03021304</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>Study of Mepolizumab Safety Syringe in Asthmatics</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>56</td>\n",
       "      <td>February 1, 2017</td>\n",
       "      <td>August 8, 2017</td>\n",
       "      <td>Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>Drug: Mepolizumab</td>\n",
       "      <td>Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, subc...</td>\n",
       "      <td>Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe</td>\n",
       "      <td>[Primary, Secondary]</td>\n",
       "      <td>[Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...</td>\n",
       "      <td>[During the clinic visits the Investigator or designee evaluated if the participants were able t...</td>\n",
       "      <td>[Week 8, Week 4]</td>\n",
       "      <td>[100, 100]</td>\n",
       "      <td>[Percentage of participants, Percentage of participants]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT03099096</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>Study of Mepolizumab Autoinjector in Asthmatics</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>159</td>\n",
       "      <td>May 4, 2017</td>\n",
       "      <td>November 30, 2017</td>\n",
       "      <td>Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>Drug: Mepolizumab</td>\n",
       "      <td>Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the ...</td>\n",
       "      <td>Mepolizumab SC 100 mg/milliliter (mL) in autoinjector</td>\n",
       "      <td>[Primary, Primary, Secondary, Secondary]</td>\n",
       "      <td>[Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...</td>\n",
       "      <td>[Due to differences in the labelling requirements among regulatory authorities around the world,...</td>\n",
       "      <td>[Week 8, Week 8, Week 4, Week 4]</td>\n",
       "      <td>[99, 98, 98, 96]</td>\n",
       "      <td>[Percentage of participants, Percentage of Participants, Percentage of participants, Percentage ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>NCT01508936</td>\n",
       "      <td>Teva Branded Pharmaceutical Products R&amp;D, Inc.</td>\n",
       "      <td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...</td>\n",
       "      <td>Eosinophilic Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>511</td>\n",
       "      <td>February 2012</td>\n",
       "      <td>August 2013</td>\n",
       "      <td>Inclusion criteria:\\n\\nPatients are included in the study if all of the following criteria are m...</td>\n",
       "      <td>Reslizumab, Placebo</td>\n",
       "      <td>Drug: Placebo, Drug: Reslizumab</td>\n",
       "      <td>Placebo intravenous injection every 4 weeks for a total of 4 doses., Reslizumab intravenous inje...</td>\n",
       "      <td>Reslizumab 3.0 mg/kg, Placebo</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n",
       "      <td>[Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis...</td>\n",
       "      <td>[FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the ...</td>\n",
       "      <td>[Baseline (Day 1), Week 16, Baseline (Day 1), Weeks 4, 8, 12, 16, Baseline (Day 1), Weeks 4, 8, ...</td>\n",
       "      <td>[-0.2778, 0.0229, 0.175, 0.251, -0.614, -0.737, -0.2944, 0.0271, 0.164, 0.224, 0.199, 0.249, 0.1...</td>\n",
       "      <td>[FEV1 liters/ eosinophils 10^9/liter, liters, units on a scale, FEV1 liters/ eosinophils 10^9/li...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NCT03557307</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adu...</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>598</td>\n",
       "      <td>August 1, 2018</td>\n",
       "      <td>April 16, 2021</td>\n",
       "      <td>Inclusion Criteria:\\n\\nPeripheral blood eosinophil count of ≥150 cells/μL assessed by central la...</td>\n",
       "      <td>Benralizumab</td>\n",
       "      <td>Biological: Benralizumab</td>\n",
       "      <td>Benralizumab subcutaneous injection</td>\n",
       "      <td>Benralizumab</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NCT02135692</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>339</td>\n",
       "      <td>May 29, 2014</td>\n",
       "      <td>October 5, 2017</td>\n",
       "      <td>Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...</td>\n",
       "      <td>Mepolizumab, SOC</td>\n",
       "      <td>Biological: Mepolizumab, Drug: SOC</td>\n",
       "      <td>All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approxim...</td>\n",
       "      <td>Mepolizumab 100 mg, Mepolizumab 100 mg</td>\n",
       "      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n",
       "      <td>[Annualized Rate of On-treatment Exacerbations Per Year, Number of Participants With Any On-trea...</td>\n",
       "      <td>[Exacerbations are defined as the worsening of asthma which requires use of systemic corticoster...</td>\n",
       "      <td>[Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 168, Ba...</td>\n",
       "      <td>[0.93, 315, 84, -0.16, -0.15, -0.21, -0.17, -0.18, -0.08, -0.03, -0.12, -0.06, -0.01, -0.09, 0.3...</td>\n",
       "      <td>[Exacerbations per year, Participants, Scores on a scale, Milliliter, Participants, Participants...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>NCT02836496</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)</td>\n",
       "      <td>Hypereosinophilic Syndrome</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>108</td>\n",
       "      <td>March 7, 2017</td>\n",
       "      <td>August 8, 2019</td>\n",
       "      <td>Inclusion Criteria:\\n\\nCapable of giving signed informed consent/assent which includes complianc...</td>\n",
       "      <td>Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or pred...</td>\n",
       "      <td>Drug: Mepolizumab 300 mg, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Pla...</td>\n",
       "      <td>Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 we...</td>\n",
       "      <td>Mepolizumab, Placebo, Mepolizumab, Placebo, Mepolizumab, Placebo</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary]</td>\n",
       "      <td>[Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During t...</td>\n",
       "      <td>[Percentage of participants who experienced &gt;=1 HES flare during the 32-Week treatment period or...</td>\n",
       "      <td>[Up to Week 32, Week 20 to Week 32, Weeks 4, 8, 12, 16, 20, 24, 28 and 32, Up to Week 32, Baseli...</td>\n",
       "      <td>[56, 28, 35, 17, 7.4, 5.6, 14.9, 7.4, 26.2, 9.3, 33.8, 13.0, 41.3, 13.0, 48.9, 14.8, 50.8, 20.5,...</td>\n",
       "      <td>[Percentage of participants, Percentage of participants, Probability expressed as percentage, Fl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>NCT04718389</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants Wi...</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>1700</td>\n",
       "      <td>January 26, 2021</td>\n",
       "      <td>December 15, 2023</td>\n",
       "      <td>Key inclusion criteria for study:\\n\\nAdult and adolescent participants more than or equal to (&gt;=...</td>\n",
       "      <td>GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled...</td>\n",
       "      <td>Biological: GSK3511294 (Depemokimab), Biological: Placebo, Drug: Standard of care (SoC), Device:...</td>\n",
       "      <td>Participants will receive GSK3511294 (Depemokimab) plus placebo treatment matching the active co...</td>\n",
       "      <td>Participants receiving GSK3511294 (Depemokimab) plus placebo matching prior anti-IL-5/5R treatme...</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>NCT04718103</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phen...</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>375</td>\n",
       "      <td>February 25, 2021</td>\n",
       "      <td>August 23, 2023</td>\n",
       "      <td>Key inclusion criteria for study:\\n\\nAdults and adolescents &gt;=12 years of age, at the time of si...</td>\n",
       "      <td>GSK3511294 (Depemokimab), Placebo, Standard of Care, Pre-filled Syringe</td>\n",
       "      <td>Biological: GSK3511294 (Depemokimab), Drug: Standard of Care, Device: Pre-filled Syringe, Biolog...</td>\n",
       "      <td>Participants will receive GSK3511294 (Depemokimab) during the study. All participants will conti...</td>\n",
       "      <td>Participants receiving GSK3511294 (Depemokimab), Participants receiving Placebo, Participants re...</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>NCT04719832</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Se...</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>375</td>\n",
       "      <td>March 17, 2021</td>\n",
       "      <td>October 3, 2023</td>\n",
       "      <td>Key inclusion Criteria:\\n\\nAdults and adolescents greater than or equal to (&gt;=)12 years of age, ...</td>\n",
       "      <td>GSK3511294 (Depemokimab), Placebo, Standard of care, Pre-filled Syringe</td>\n",
       "      <td>Biological: GSK3511294 (Depemokimab), Drug: Standard of care, Device: Pre-filled Syringe, Drug: ...</td>\n",
       "      <td>Participants will be administered GSK3511294 (Depemokimab) along with SoC., Participants will be...</td>\n",
       "      <td>Participants receiving GSK3511294 (Depemokimab), Participants receiving placebo, Participants re...</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NCT02869438</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>233</td>\n",
       "      <td>November 9, 2016</td>\n",
       "      <td>August 1, 2018</td>\n",
       "      <td>Inclusion criteria\\n\\nWritten informed consent for study participation must be obtained prior to...</td>\n",
       "      <td>Benralizumab, Placebo</td>\n",
       "      <td>Drug: Benralizumab, Other: Placebo</td>\n",
       "      <td>Benralizumab administered subcutaneously, Placebo administered subcutaneously</td>\n",
       "      <td>Benralizumab arm, Placebo arm</td>\n",
       "      <td>[Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...</td>\n",
       "      <td>[Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in ...</td>\n",
       "      <td>[The average over the mean differences between benralizumab and placebo for change from baseline...</td>\n",
       "      <td>[From first IP dose to Day 84, From first IP dose to Day 84, From first IP dose to Day 84, From ...</td>\n",
       "      <td>[0.21, 0.132, 0.22, 0.203, 0.209, 0.149, -0.415, -0.208, -88.55, 11.55, 0.104, 0.081, 0.125, 0.0...</td>\n",
       "      <td>[Liter, Liter, Percent change, Liter, Liter, Percentage of Participants, Score on a scale, Score...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>NCT03562195</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>300</td>\n",
       "      <td>August 29, 2018</td>\n",
       "      <td>November 30, 2022</td>\n",
       "      <td>Inclusion Criteria:\\n\\nSubjects who will be able to give written informed consent prior to parti...</td>\n",
       "      <td>Mepolizumab 100 milligrams, Placebo, Salbutamol</td>\n",
       "      <td>Drug: Mepolizumab 100 milligrams, Drug: Salbutamol, Drug: Placebo, Drug: Salbutamol</td>\n",
       "      <td>Eligible subjects will randomized in 1:1 ratio to Mepolizumab group or Placebo group. Subjects i...</td>\n",
       "      <td>Subjects receiving Mepolizumab, Subjects receiving Placebo, Subjects receiving Mepolizumab, Subj...</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>NCT02049294</td>\n",
       "      <td>McMaster University</td>\n",
       "      <td>Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophi...</td>\n",
       "      <td>Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis</td>\n",
       "      <td>Phase 2, Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>11</td>\n",
       "      <td>March 2014</td>\n",
       "      <td>September 2017</td>\n",
       "      <td>Inclusion criteria\\n\\nConfirmed asthma within the past 2 years (12% bronchodilator reversibility...</td>\n",
       "      <td>Omalizumab (Xolair), Placebo</td>\n",
       "      <td>Drug: Placebo, Biological: Omalizumab (Xolair)</td>\n",
       "      <td>Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level., 0.9% normal sal...</td>\n",
       "      <td>Placebo (Normal Saline), Omalizumab (Xolair)</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>NCT01520051</td>\n",
       "      <td>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</td>\n",
       "      <td>Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations</td>\n",
       "      <td>Asthma, Viral Infection</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>48</td>\n",
       "      <td>January 2012</td>\n",
       "      <td>December 2013</td>\n",
       "      <td>Inclusion Criteria:\\n\\nAge between 18 - 50 years\\nHistory of episodic chest tightness and wheezi...</td>\n",
       "      <td>Mepolizumab, Placebo</td>\n",
       "      <td>Drug: Mepolizumab, Drug: Placebo</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Mepolizumab, Saline</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>NCT03170271</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontroll...</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>660</td>\n",
       "      <td>July 7, 2017</td>\n",
       "      <td>September 25, 2019</td>\n",
       "      <td>Inclusion Criteria:\\n\\nFemale and male patients aged 18 to 75 years inclusively at the time of V...</td>\n",
       "      <td>Benralizumab (Medi-563), Placebo</td>\n",
       "      <td>Drug: Benralizumab (Medi-563), Drug: Placebo</td>\n",
       "      <td>Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 day...</td>\n",
       "      <td>Benralizumab (Medi-563), Placebo</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n",
       "      <td>[Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24), Change From ...</td>\n",
       "      <td>[An asthma exacerbation was defined as a worsening of asthma that led to any of the following:\\n...</td>\n",
       "      <td>[Baseline (Week 0) up to Week 24, Baseline (Week 0) and Week 24, Baseline (Week 0) and Week 24, ...</td>\n",
       "      <td>[0.94, 1.86, -23.06, -14.94, 0.30, 0.14, -1.47, -1.01, 123, 107, 27.17, 7.06, 16.47, -6.61, 17.7...</td>\n",
       "      <td>[Events/year, Scores on a scale, Liters (L), Scores on a scale, Participants, L/minute, Scores o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>NCT05030155</td>\n",
       "      <td>Assistance Publique - Hôpitaux de Paris</td>\n",
       "      <td>Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients Wit...</td>\n",
       "      <td>Eosinophilic Granulomatosis With Polyangiitis</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>100</td>\n",
       "      <td>December 2021</td>\n",
       "      <td>December 2024</td>\n",
       "      <td>Inclusion Criteria:\\n\\nPatients with a diagnosis of EGPA independently of ANCA status,\\nPatients...</td>\n",
       "      <td>Mepolizumab, cyclophosphamide/azathioprine, Placebo</td>\n",
       "      <td>Drug: Mepolizumab, Drug: Placebo, Drug: Mepolizumab, Drug: Placebo, Drug: cyclophosphamide/azath...</td>\n",
       "      <td>Mepolizumab 300mg every 4 weeks until D336, Placebo of Mepolizumab every 4 weeks until D336, Mep...</td>\n",
       "      <td>Patients with FFS=0 - Mepolizumab, Patients with FFS≥1 - Mepolizumab, Patients with FFS≥1 - Plac...</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>NCT01842607</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>651</td>\n",
       "      <td>May 27, 2013</td>\n",
       "      <td>March 13, 2015</td>\n",
       "      <td>Inclusion Criteria:\\n\\nFrench subjects: In France, a subject will be eligible for inclusion in t...</td>\n",
       "      <td>Mepolizumab</td>\n",
       "      <td>Biological: Mepolizumab</td>\n",
       "      <td>Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (...</td>\n",
       "      <td>Mepolizumab Arm</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...</td>\n",
       "      <td>[Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunog...</td>\n",
       "      <td>[AEs were collected from the Baseline visit until the follow-up visit (approx. 12 weeks post-las...</td>\n",
       "      <td>[From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-l...</td>\n",
       "      <td>[558, 119, 94, 1, 0, 31, 615, 0, 31, 0.93, -0.09, -0.11, -0.05, -0.10, -0.09, 0.20, 67, 50, 29, ...</td>\n",
       "      <td>[Participants, Participants, Exacerbations per year, Score on scale, Milliliters (mL), Participa...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>NCT01691508</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>135</td>\n",
       "      <td>October 2012</td>\n",
       "      <td>December 2013</td>\n",
       "      <td>Inclusion Criteria:\\n\\nInformed Consent and Study Compliance: Subjects must be able to give writ...</td>\n",
       "      <td>Mepolizumab, Placebo, OCS (prednisone/prednisolone)</td>\n",
       "      <td>Drug: Mepolizumab, Drug: OCS (prednisone/prednisolone), Drug: Placebo, Drug: OCS (prednisone/pre...</td>\n",
       "      <td>Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20, Placebo subcutaneous once every...</td>\n",
       "      <td>Mepolizumab, Placebo, Mepolizumab, Placebo</td>\n",
       "      <td>[Primary, Secondary, Secondary, Secondary, Secondary]</td>\n",
       "      <td>[Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroi...</td>\n",
       "      <td>[Baseline (BL) dose was the prescribed optimized prednisone/prednisolone dose following the OCS ...</td>\n",
       "      <td>[Baseline; Weeks 20 to 24, Baseline; Weeks 20 to 24, Weeks 20 to 24, Weeks 20 to 24, Baseline; W...</td>\n",
       "      <td>[7, 16, 5, 12, 10, 9, 7, 7, 37, 25, 22, 37, 44, 32, 21, 37, 45, 32, 5, 10, 61, 59, 0.0, -50.0]</td>\n",
       "      <td>[Participants, Participants, Participants, Participants, Percentage reduction in OCS dose]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>NCT00380926</td>\n",
       "      <td>Johann Wolfgang Goethe University Hospital</td>\n",
       "      <td>Fish Oil and Asthma in House Dust Mite Allergy</td>\n",
       "      <td>Allergic Asthma, Bronchial Inflammation, House Dust Mite Allergy</td>\n",
       "      <td>Phase 2, Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>23</td>\n",
       "      <td>April 2004</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Inclusion Criteria:\\n\\nallergic sensitization to house dust mite as proven by skin test and spec...</td>\n",
       "      <td>polyunsatturated fatty acids (fish oil)</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>NCT03327701</td>\n",
       "      <td>Louis-Philippe Boulet</td>\n",
       "      <td>The Effect of Benralizumab on Exercise-induced Bronchoconstriction</td>\n",
       "      <td>Asthma, Exercise-Induced</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>40</td>\n",
       "      <td>December 2017</td>\n",
       "      <td>December 2019</td>\n",
       "      <td>Inclusion Criteria:\\n\\nWritten informed consent for study participants must be obtained prior to...</td>\n",
       "      <td>Benralizumab</td>\n",
       "      <td>Drug: Benralizumab, Drug: Benralizumab</td>\n",
       "      <td>Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed b...</td>\n",
       "      <td>Experimental, Placebo</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>NCT01463644</td>\n",
       "      <td>McMaster University</td>\n",
       "      <td>Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis</td>\n",
       "      <td>Chronic Obstructive Pulmonary Diseases, Chronic Airways Limitation, Bronchitis</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>19</td>\n",
       "      <td>January 2012</td>\n",
       "      <td>August 2015</td>\n",
       "      <td>Inclusion Criteria:\\n\\nDiagnosis: An established clinical history of COPD in accordance with the...</td>\n",
       "      <td>Mepolizumab, placebo</td>\n",
       "      <td>Drug: Mepolizumab, Drug: placebo</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>mepolizumab, placebo</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>NCT04157335</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis Wi...</td>\n",
       "      <td>Nasal Polyposis</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>276</td>\n",
       "      <td>November 25, 2019</td>\n",
       "      <td>June 2, 2023</td>\n",
       "      <td>Inclusion criteria:\\n\\nFemale or male patients aged 18 to 75 years inclusive\\nStable Intranasal ...</td>\n",
       "      <td>Benralizumab 30 mg, Matched placebo</td>\n",
       "      <td>Biological: Benralizumab 30 mg, Biological: Matched placebo</td>\n",
       "      <td>Benralizumab administered subcutaneously, Placebo administered subcutaneously</td>\n",
       "      <td>Benralizumab, Placebo</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "      <td>Unreported</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          NCTId  \\\n",
       "0   NCT01285323   \n",
       "1   NCT01287039   \n",
       "2   NCT01270464   \n",
       "3   NCT01290887   \n",
       "4   NCT02594332   \n",
       "5   NCT02555371   \n",
       "6   NCT02281318   \n",
       "7   NCT04305405   \n",
       "8   NCT03052725   \n",
       "9   NCT02559791   \n",
       "10  NCT04049175   \n",
       "11  NCT03470311   \n",
       "12  NCT03021304   \n",
       "13  NCT03099096   \n",
       "14  NCT01508936   \n",
       "15  NCT03557307   \n",
       "16  NCT02135692   \n",
       "17  NCT02836496   \n",
       "18  NCT04718389   \n",
       "19  NCT04718103   \n",
       "20  NCT04719832   \n",
       "21  NCT02869438   \n",
       "22  NCT03562195   \n",
       "23  NCT02049294   \n",
       "24  NCT01520051   \n",
       "25  NCT03170271   \n",
       "26  NCT05030155   \n",
       "27  NCT01842607   \n",
       "28  NCT01691508   \n",
       "29  NCT00380926   \n",
       "30  NCT03327701   \n",
       "31  NCT01463644   \n",
       "32  NCT04157335   \n",
       "\n",
       "                                                      LeadSponsorName  \\\n",
       "0                      Teva Branded Pharmaceutical Products R&D, Inc.   \n",
       "1                      Teva Branded Pharmaceutical Products R&D, Inc.   \n",
       "2                      Teva Branded Pharmaceutical Products R&D, Inc.   \n",
       "3                      Teva Branded Pharmaceutical Products R&D, Inc.   \n",
       "4                                 Johannes Gutenberg University Mainz   \n",
       "5                                                     GlaxoSmithKline   \n",
       "6                                                     GlaxoSmithKline   \n",
       "7                                                         AstraZeneca   \n",
       "8                      Teva Branded Pharmaceutical Products R&D, Inc.   \n",
       "9                                                 McMaster University   \n",
       "10                                         Chiesi Farmaceutici S.p.A.   \n",
       "11                                                McMaster University   \n",
       "12                                                    GlaxoSmithKline   \n",
       "13                                                    GlaxoSmithKline   \n",
       "14                     Teva Branded Pharmaceutical Products R&D, Inc.   \n",
       "15                                                        AstraZeneca   \n",
       "16                                                    GlaxoSmithKline   \n",
       "17                                                    GlaxoSmithKline   \n",
       "18                                                    GlaxoSmithKline   \n",
       "19                                                    GlaxoSmithKline   \n",
       "20                                                    GlaxoSmithKline   \n",
       "21                                                        AstraZeneca   \n",
       "22                                                    GlaxoSmithKline   \n",
       "23                                                McMaster University   \n",
       "24  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)   \n",
       "25                                                        AstraZeneca   \n",
       "26                            Assistance Publique - Hôpitaux de Paris   \n",
       "27                                                    GlaxoSmithKline   \n",
       "28                                                    GlaxoSmithKline   \n",
       "29                         Johann Wolfgang Goethe University Hospital   \n",
       "30                                              Louis-Philippe Boulet   \n",
       "31                                                McMaster University   \n",
       "32                                                        AstraZeneca   \n",
       "\n",
       "                                                                                             BriefTitle  \\\n",
       "0        A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma   \n",
       "1   A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinic...   \n",
       "2   A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Pa...   \n",
       "3   Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/k...   \n",
       "4   Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic As...   \n",
       "5         Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients   \n",
       "6   Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinoph...   \n",
       "7          PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma   \n",
       "8           A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma   \n",
       "9        Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma   \n",
       "10             Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma   \n",
       "11          Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies   \n",
       "12                                                    Study of Mepolizumab Safety Syringe in Asthmatics   \n",
       "13                                                      Study of Mepolizumab Autoinjector in Asthmatics   \n",
       "14  Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to S...   \n",
       "15  Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adu...   \n",
       "16     A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects   \n",
       "17    Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)   \n",
       "18  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants Wi...   \n",
       "19  A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phen...   \n",
       "20  Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Se...   \n",
       "21  A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benraliz...   \n",
       "22                            A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma   \n",
       "23  Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophi...   \n",
       "24                                    Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations   \n",
       "25  A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontroll...   \n",
       "26  Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients Wit...   \n",
       "27                           A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects   \n",
       "28                          Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma   \n",
       "29                                                       Fish Oil and Asthma in House Dust Mite Allergy   \n",
       "30                                   The Effect of Benralizumab on Exercise-induced Bronchoconstriction   \n",
       "31            Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis   \n",
       "32  Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis Wi...   \n",
       "\n",
       "                                                                         Condition  \\\n",
       "0                                                              Eosinophilic Asthma   \n",
       "1                                                              Eosinophilic Asthma   \n",
       "2                                                              Eosinophilic Asthma   \n",
       "3                                                              Eosinophilic Asthma   \n",
       "4                                                                           Asthma   \n",
       "5                                                                           Asthma   \n",
       "6                                                                           Asthma   \n",
       "7                                                       Severe Uncontrolled Asthma   \n",
       "8                                                              Eosinophils, Asthma   \n",
       "9                                Severe Persistent Asthma, Eosinophilic Bronchitis   \n",
       "10                                                            Asthma; Eosinophilic   \n",
       "11                                 Severe Prednisone Dependent Eosinophilic Asthma   \n",
       "12                                                                          Asthma   \n",
       "13                                                                          Asthma   \n",
       "14                                                             Eosinophilic Asthma   \n",
       "15                                                                          Asthma   \n",
       "16                                                                          Asthma   \n",
       "17                                                      Hypereosinophilic Syndrome   \n",
       "18                                                                          Asthma   \n",
       "19                                                                          Asthma   \n",
       "20                                                                          Asthma   \n",
       "21                                                                          Asthma   \n",
       "22                                                                          Asthma   \n",
       "23             Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis   \n",
       "24                                                         Asthma, Viral Infection   \n",
       "25                                                                          Asthma   \n",
       "26                                   Eosinophilic Granulomatosis With Polyangiitis   \n",
       "27                                                                          Asthma   \n",
       "28                                                                          Asthma   \n",
       "29                Allergic Asthma, Bronchial Inflammation, House Dust Mite Allergy   \n",
       "30                                                        Asthma, Exercise-Induced   \n",
       "31  Chronic Obstructive Pulmonary Diseases, Chronic Airways Limitation, Bronchitis   \n",
       "32                                                                 Nasal Polyposis   \n",
       "\n",
       "               Phase       StudyType EnrollmentCount          StartDate  \\\n",
       "0            Phase 3  Interventional             464         March 2011   \n",
       "1            Phase 3  Interventional             489         April 2011   \n",
       "2            Phase 3  Interventional             315      February 2011   \n",
       "3            Phase 3  Interventional            1052          June 2011   \n",
       "4            Phase 3  Interventional              29  November 17, 2015   \n",
       "5            Phase 3  Interventional             306    January 7, 2016   \n",
       "6            Phase 3  Interventional             556  December 11, 2014   \n",
       "7            Phase 3  Interventional              30  November 21, 2019   \n",
       "8            Phase 3  Interventional             391     March 10, 2017   \n",
       "9   Phase 2, Phase 3  Interventional              10       October 2015   \n",
       "10           Phase 3  Interventional             810    August 28, 2019   \n",
       "11           Phase 3  Interventional              20     April 26, 2018   \n",
       "12           Phase 3  Interventional              56   February 1, 2017   \n",
       "13           Phase 3  Interventional             159        May 4, 2017   \n",
       "14           Phase 3  Interventional             511      February 2012   \n",
       "15           Phase 3  Interventional             598     August 1, 2018   \n",
       "16           Phase 3  Interventional             339       May 29, 2014   \n",
       "17           Phase 3  Interventional             108      March 7, 2017   \n",
       "18           Phase 3  Interventional            1700   January 26, 2021   \n",
       "19           Phase 3  Interventional             375  February 25, 2021   \n",
       "20           Phase 3  Interventional             375     March 17, 2021   \n",
       "21           Phase 3  Interventional             233   November 9, 2016   \n",
       "22           Phase 3  Interventional             300    August 29, 2018   \n",
       "23  Phase 2, Phase 3  Interventional              11         March 2014   \n",
       "24           Phase 3  Interventional              48       January 2012   \n",
       "25           Phase 3  Interventional             660       July 7, 2017   \n",
       "26           Phase 3  Interventional             100      December 2021   \n",
       "27           Phase 3  Interventional             651       May 27, 2013   \n",
       "28           Phase 3  Interventional             135       October 2012   \n",
       "29  Phase 2, Phase 3  Interventional              23         April 2004   \n",
       "30           Phase 3  Interventional              40      December 2017   \n",
       "31           Phase 3  Interventional              19       January 2012   \n",
       "32           Phase 3  Interventional             276  November 25, 2019   \n",
       "\n",
       "   PrimaryCompletionDate  \\\n",
       "0             April 2014   \n",
       "1          December 2013   \n",
       "2         September 2013   \n",
       "3           January 2015   \n",
       "4           May 22, 2017   \n",
       "5          July 24, 2019   \n",
       "6          June 10, 2016   \n",
       "7       October 31, 2022   \n",
       "8      February 22, 2018   \n",
       "9             April 2017   \n",
       "10      October 19, 2020   \n",
       "11            April 2022   \n",
       "12        August 8, 2017   \n",
       "13     November 30, 2017   \n",
       "14           August 2013   \n",
       "15        April 16, 2021   \n",
       "16       October 5, 2017   \n",
       "17        August 8, 2019   \n",
       "18     December 15, 2023   \n",
       "19       August 23, 2023   \n",
       "20       October 3, 2023   \n",
       "21        August 1, 2018   \n",
       "22     November 30, 2022   \n",
       "23        September 2017   \n",
       "24         December 2013   \n",
       "25    September 25, 2019   \n",
       "26         December 2024   \n",
       "27        March 13, 2015   \n",
       "28         December 2013   \n",
       "29            Unreported   \n",
       "30         December 2019   \n",
       "31           August 2015   \n",
       "32          June 2, 2023   \n",
       "\n",
       "                                                                                    EligibilityCriteria  \\\n",
       "0   Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...   \n",
       "1   Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...   \n",
       "2   Inclusion Criteria:\\n\\nThe patient is male or female, 12 through 75 years of age, with a previou...   \n",
       "3   Inclusion Criteria:\\n\\nWritten informed consent is obtained.\\nPatient must have completed treatm...   \n",
       "4   Inclusion Criteria:\\n\\nPatients must be able to give written informed consent prior to participa...   \n",
       "5   Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...   \n",
       "6   Inclusion Criteria:\\n\\nAge: At least 12 years of age at the time of signing the informed consent...   \n",
       "7   Inclusion Criteria:\\n\\nPatients are eligible to be included in the study only if all of the foll...   \n",
       "8   Inclusion Criteria:\\n\\n• Patient with eosinophilic asthma who completed the treatment period of ...   \n",
       "9   Inclusion Criteria:\\n\\nInformed consent Prior to the beginning of the study, patients must be wi...   \n",
       "10  Inclusion Criteria:\\n\\nMale or female subjects aged ≥12 years and ≤75 years with a diagnosis of ...   \n",
       "11  Inclusion Criteria:\\n\\nInformed consent Prior to the beginning of the study, patients must be wi...   \n",
       "12  Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...   \n",
       "13  Inclusion Criteria:\\n\\nAge: At least 12 years of age inclusive, at the time of signing the infor...   \n",
       "14  Inclusion criteria:\\n\\nPatients are included in the study if all of the following criteria are m...   \n",
       "15  Inclusion Criteria:\\n\\nPeripheral blood eosinophil count of ≥150 cells/μL assessed by central la...   \n",
       "16  Inclusion Criteria:\\n\\nInformed Consent: Prior to commencing any study related activities, subje...   \n",
       "17  Inclusion Criteria:\\n\\nCapable of giving signed informed consent/assent which includes complianc...   \n",
       "18  Key inclusion criteria for study:\\n\\nAdult and adolescent participants more than or equal to (>=...   \n",
       "19  Key inclusion criteria for study:\\n\\nAdults and adolescents >=12 years of age, at the time of si...   \n",
       "20  Key inclusion Criteria:\\n\\nAdults and adolescents greater than or equal to (>=)12 years of age, ...   \n",
       "21  Inclusion criteria\\n\\nWritten informed consent for study participation must be obtained prior to...   \n",
       "22  Inclusion Criteria:\\n\\nSubjects who will be able to give written informed consent prior to parti...   \n",
       "23  Inclusion criteria\\n\\nConfirmed asthma within the past 2 years (12% bronchodilator reversibility...   \n",
       "24  Inclusion Criteria:\\n\\nAge between 18 - 50 years\\nHistory of episodic chest tightness and wheezi...   \n",
       "25  Inclusion Criteria:\\n\\nFemale and male patients aged 18 to 75 years inclusively at the time of V...   \n",
       "26  Inclusion Criteria:\\n\\nPatients with a diagnosis of EGPA independently of ANCA status,\\nPatients...   \n",
       "27  Inclusion Criteria:\\n\\nFrench subjects: In France, a subject will be eligible for inclusion in t...   \n",
       "28  Inclusion Criteria:\\n\\nInformed Consent and Study Compliance: Subjects must be able to give writ...   \n",
       "29  Inclusion Criteria:\\n\\nallergic sensitization to house dust mite as proven by skin test and spec...   \n",
       "30  Inclusion Criteria:\\n\\nWritten informed consent for study participants must be obtained prior to...   \n",
       "31  Inclusion Criteria:\\n\\nDiagnosis: An established clinical history of COPD in accordance with the...   \n",
       "32  Inclusion criteria:\\n\\nFemale or male patients aged 18 to 75 years inclusive\\nStable Intranasal ...   \n",
       "\n",
       "                                                                                       InterventionName  \\\n",
       "0                                                                                   Reslizumab, Placebo   \n",
       "1                                                                                   Reslizumab, Placebo   \n",
       "2                                                                                   Reslizumab, Placebo   \n",
       "3                                                                                            Reslizumab   \n",
       "4                                                                                  Mepolizumab, Placebo   \n",
       "5                                                                            Mepolizumab 100mg, Placebo   \n",
       "6                                                                             Mepolizumab, Placebo, SOC   \n",
       "7                                                                                          Benralizumab   \n",
       "8                                                                                            reslizumab   \n",
       "9                                                                                   Reslizumab, Placebo   \n",
       "10                                                   Treatment A, Treatment B, Treatment C, Treatment D   \n",
       "11                                                                                Benralizumab, Placebo   \n",
       "12                                                                                          Mepolizumab   \n",
       "13                                                                                          Mepolizumab   \n",
       "14                                                                                  Reslizumab, Placebo   \n",
       "15                                                                                         Benralizumab   \n",
       "16                                                                                     Mepolizumab, SOC   \n",
       "17  Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or pred...   \n",
       "18  GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled...   \n",
       "19                              GSK3511294 (Depemokimab), Placebo, Standard of Care, Pre-filled Syringe   \n",
       "20                              GSK3511294 (Depemokimab), Placebo, Standard of care, Pre-filled Syringe   \n",
       "21                                                                                Benralizumab, Placebo   \n",
       "22                                                      Mepolizumab 100 milligrams, Placebo, Salbutamol   \n",
       "23                                                                         Omalizumab (Xolair), Placebo   \n",
       "24                                                                                 Mepolizumab, Placebo   \n",
       "25                                                                     Benralizumab (Medi-563), Placebo   \n",
       "26                                                  Mepolizumab, cyclophosphamide/azathioprine, Placebo   \n",
       "27                                                                                          Mepolizumab   \n",
       "28                                                  Mepolizumab, Placebo, OCS (prednisone/prednisolone)   \n",
       "29                                                              polyunsatturated fatty acids (fish oil)   \n",
       "30                                                                                         Benralizumab   \n",
       "31                                                                                 Mepolizumab, placebo   \n",
       "32                                                                  Benralizumab 30 mg, Matched placebo   \n",
       "\n",
       "                                                                               ArmGroupInterventionName  \\\n",
       "0                                                                       Drug: Placebo, Drug: Reslizumab   \n",
       "1                                                                       Drug: Placebo, Drug: Reslizumab   \n",
       "2                                                     Drug: Placebo, Drug: Reslizumab, Drug: Reslizumab   \n",
       "3                                                                                      Drug: Reslizumab   \n",
       "4                                                                      Drug: Mepolizumab, Drug: Placebo   \n",
       "5                           Biological: Mepolizumab 100mg, Biological: Mepolizumab 100mg, Drug: Placebo   \n",
       "6                                          Biological: Mepolizumab, Drug: SOC, Drug: Placebo, Drug: SOC   \n",
       "7                                                                Drug: Benralizumab, Drug: Benralizumab   \n",
       "8                                                                                      Drug: reslizumab   \n",
       "9                                                                 Biological: Reslizumab, Drug: Placebo   \n",
       "10                           Drug: Treatment A, Drug: Treatment B, Drug: Treatment C, Drug: Treatment D   \n",
       "11                                                        Biological: Benralizumab, Biological: Placebo   \n",
       "12                                                                                    Drug: Mepolizumab   \n",
       "13                                                                                    Drug: Mepolizumab   \n",
       "14                                                                      Drug: Placebo, Drug: Reslizumab   \n",
       "15                                                                             Biological: Benralizumab   \n",
       "16                                                                   Biological: Mepolizumab, Drug: SOC   \n",
       "17  Drug: Mepolizumab 300 mg, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Pla...   \n",
       "18  Biological: GSK3511294 (Depemokimab), Biological: Placebo, Drug: Standard of care (SoC), Device:...   \n",
       "19  Biological: GSK3511294 (Depemokimab), Drug: Standard of Care, Device: Pre-filled Syringe, Biolog...   \n",
       "20  Biological: GSK3511294 (Depemokimab), Drug: Standard of care, Device: Pre-filled Syringe, Drug: ...   \n",
       "21                                                                   Drug: Benralizumab, Other: Placebo   \n",
       "22                  Drug: Mepolizumab 100 milligrams, Drug: Salbutamol, Drug: Placebo, Drug: Salbutamol   \n",
       "23                                                       Drug: Placebo, Biological: Omalizumab (Xolair)   \n",
       "24                                                                     Drug: Mepolizumab, Drug: Placebo   \n",
       "25                                                         Drug: Benralizumab (Medi-563), Drug: Placebo   \n",
       "26  Drug: Mepolizumab, Drug: Placebo, Drug: Mepolizumab, Drug: Placebo, Drug: cyclophosphamide/azath...   \n",
       "27                                                                              Biological: Mepolizumab   \n",
       "28  Drug: Mepolizumab, Drug: OCS (prednisone/prednisolone), Drug: Placebo, Drug: OCS (prednisone/pre...   \n",
       "29                                                                                           Unreported   \n",
       "30                                                               Drug: Benralizumab, Drug: Benralizumab   \n",
       "31                                                                     Drug: Mepolizumab, Drug: placebo   \n",
       "32                                          Biological: Benralizumab 30 mg, Biological: Matched placebo   \n",
       "\n",
       "                                                                                    ArmGroupDescription  \\\n",
       "0   Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Resl...   \n",
       "1   Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses., Resl...   \n",
       "2   Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses., 0.3 mg/kg, ...   \n",
       "3   Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.   \n",
       "4   100 mg SC every 4 weeks for 13 injections, Amount of Placebo corresponding to mepolizumab dose S...   \n",
       "5   There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to...   \n",
       "6   Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh eve...   \n",
       "7                                                        Below 35 kilos, Greater than/equal to 35 kilos   \n",
       "8   Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or uppe...   \n",
       "9   All study participants will receive 2 monthly doses of placebo followed by 4 monthly doses of IV...   \n",
       "10  Administration of CHF 6532 Dose #1, Administration of CHF 6532 Dose #2, Administration of CHF 65...   \n",
       "11  Benralizumab 30mg in 1mL subcutaneously, Matched placebo (1mL) to active Benralizumab subcutaneo...   \n",
       "12  Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, subc...   \n",
       "13  Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the ...   \n",
       "14  Placebo intravenous injection every 4 weeks for a total of 4 doses., Reslizumab intravenous inje...   \n",
       "15                                                                  Benralizumab subcutaneous injection   \n",
       "16  All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approxim...   \n",
       "17  Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 we...   \n",
       "18  Participants will receive GSK3511294 (Depemokimab) plus placebo treatment matching the active co...   \n",
       "19  Participants will receive GSK3511294 (Depemokimab) during the study. All participants will conti...   \n",
       "20  Participants will be administered GSK3511294 (Depemokimab) along with SoC., Participants will be...   \n",
       "21                        Benralizumab administered subcutaneously, Placebo administered subcutaneously   \n",
       "22  Eligible subjects will randomized in 1:1 ratio to Mepolizumab group or Placebo group. Subjects i...   \n",
       "23  Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level., 0.9% normal sal...   \n",
       "24                                                                                           Unreported   \n",
       "25  Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 day...   \n",
       "26  Mepolizumab 300mg every 4 weeks until D336, Placebo of Mepolizumab every 4 weeks until D336, Mep...   \n",
       "27  Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (...   \n",
       "28  Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20, Placebo subcutaneous once every...   \n",
       "29                                                                                           Unreported   \n",
       "30  Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed b...   \n",
       "31                                                                                           Unreported   \n",
       "32                        Benralizumab administered subcutaneously, Placebo administered subcutaneously   \n",
       "\n",
       "                                                                              InterventionArmGroupLabel  \\\n",
       "0                                                                         Reslizumab 3.0 mg/kg, Placebo   \n",
       "1                                                                         Reslizumab 3.0 mg/kg, Placebo   \n",
       "2                                               Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg, Placebo   \n",
       "3                                                                                  Reslizumab 3.0 mg/kg   \n",
       "4                                                                                  Mepolizumab, Placebo   \n",
       "5                                                      Arm Mepolizumab 100 mg, Arm Placebo, Arm Placebo   \n",
       "6                                                Mepolizumab SC, Placebo SC, Mepolizumab SC, Placebo SC   \n",
       "7                                                                                        Dose 1, Dose 2   \n",
       "8                                                                                     reslizumab 110 mg   \n",
       "9                                                                Study participants, Study participants   \n",
       "10                                                   Treatment A, Treatment B, Treatment C, Treatment D   \n",
       "11                                                                                Benralizumab, Placebo   \n",
       "12                                              Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe   \n",
       "13                                                Mepolizumab SC 100 mg/milliliter (mL) in autoinjector   \n",
       "14                                                                        Reslizumab 3.0 mg/kg, Placebo   \n",
       "15                                                                                         Benralizumab   \n",
       "16                                                               Mepolizumab 100 mg, Mepolizumab 100 mg   \n",
       "17                                     Mepolizumab, Placebo, Mepolizumab, Placebo, Mepolizumab, Placebo   \n",
       "18  Participants receiving GSK3511294 (Depemokimab) plus placebo matching prior anti-IL-5/5R treatme...   \n",
       "19  Participants receiving GSK3511294 (Depemokimab), Participants receiving Placebo, Participants re...   \n",
       "20  Participants receiving GSK3511294 (Depemokimab), Participants receiving placebo, Participants re...   \n",
       "21                                                                        Benralizumab arm, Placebo arm   \n",
       "22  Subjects receiving Mepolizumab, Subjects receiving Placebo, Subjects receiving Mepolizumab, Subj...   \n",
       "23                                                         Placebo (Normal Saline), Omalizumab (Xolair)   \n",
       "24                                                                                  Mepolizumab, Saline   \n",
       "25                                                                     Benralizumab (Medi-563), Placebo   \n",
       "26  Patients with FFS=0 - Mepolizumab, Patients with FFS≥1 - Mepolizumab, Patients with FFS≥1 - Plac...   \n",
       "27                                                                                      Mepolizumab Arm   \n",
       "28                                                           Mepolizumab, Placebo, Mepolizumab, Placebo   \n",
       "29                                                                                           Unreported   \n",
       "30                                                                                Experimental, Placebo   \n",
       "31                                                                                 mepolizumab, placebo   \n",
       "32                                                                                Benralizumab, Placebo   \n",
       "\n",
       "                                                                                     OutcomeMeasureType  \\\n",
       "0   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n",
       "1   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n",
       "2   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n",
       "3   [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Primary, Secondary, Se...   \n",
       "4                                                                                            Unreported   \n",
       "5                                                            [Primary, Secondary, Secondary, Secondary]   \n",
       "6                                                            [Primary, Secondary, Secondary, Secondary]   \n",
       "7                                                                                            Unreported   \n",
       "8   [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n",
       "9                                                                                            Unreported   \n",
       "10                                                                                           Unreported   \n",
       "11                                                                                           Unreported   \n",
       "12                                                                                 [Primary, Secondary]   \n",
       "13                                                             [Primary, Primary, Secondary, Secondary]   \n",
       "14  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n",
       "15                                                                                           Unreported   \n",
       "16  [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n",
       "17                                                [Primary, Secondary, Secondary, Secondary, Secondary]   \n",
       "18                                                                                           Unreported   \n",
       "19                                                                                           Unreported   \n",
       "20                                                                                           Unreported   \n",
       "21  [Primary, Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, ...   \n",
       "22                                                                                           Unreported   \n",
       "23                                                                                           Unreported   \n",
       "24                                                                                           Unreported   \n",
       "25  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n",
       "26                                                                                           Unreported   \n",
       "27  [Primary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary, Secondary...   \n",
       "28                                                [Primary, Secondary, Secondary, Secondary, Secondary]   \n",
       "29                                                                                           Unreported   \n",
       "30                                                                                           Unreported   \n",
       "31                                                                                           Unreported   \n",
       "32                                                                                           Unreported   \n",
       "\n",
       "                                                                                    OutcomeMeasureTitle  \\\n",
       "0   [Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...   \n",
       "1   [Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment, Change From Ba...   \n",
       "2   [Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed M...   \n",
       "3   [Participants With Treatment-Emergent Adverse Events, Participants With Treatment-Emergent Poten...   \n",
       "4                                                                                            Unreported   \n",
       "5   [Percentage of Participants With First Clinically Significant Exacerbation in Part C, Ratio to B...   \n",
       "6   [Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 2...   \n",
       "7                                                                                            Unreported   \n",
       "8   [Participants With Treatment-Emergent Adverse Events (TEAEs), Participants With Potentially Clin...   \n",
       "9                                                                                            Unreported   \n",
       "10                                                                                           Unreported   \n",
       "11                                                                                           Unreported   \n",
       "12  [Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...   \n",
       "13  [Percentage of Participants With Successful Self-administration of Their Observed Third Dose at ...   \n",
       "14  [Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis...   \n",
       "15                                                                                           Unreported   \n",
       "16  [Annualized Rate of On-treatment Exacerbations Per Year, Number of Participants With Any On-trea...   \n",
       "17  [Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During t...   \n",
       "18                                                                                           Unreported   \n",
       "19                                                                                           Unreported   \n",
       "20                                                                                           Unreported   \n",
       "21  [Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in ...   \n",
       "22                                                                                           Unreported   \n",
       "23                                                                                           Unreported   \n",
       "24                                                                                           Unreported   \n",
       "25  [Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24), Change From ...   \n",
       "26                                                                                           Unreported   \n",
       "27  [Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunog...   \n",
       "28  [Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroi...   \n",
       "29                                                                                           Unreported   \n",
       "30                                                                                           Unreported   \n",
       "31                                                                                           Unreported   \n",
       "32                                                                                           Unreported   \n",
       "\n",
       "                                                                              OutcomeMeasureDescription  \\\n",
       "0   [An exacerbation event was considered a CAE if the patient met either or both of the criteria li...   \n",
       "1   [An exacerbation event was considered a CAE if the patient met either or both of the criteria li...   \n",
       "2   [FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained fr...   \n",
       "3   [An adverse event was defined in the protocol as any untoward medical occurrence that develops o...   \n",
       "4                                                                                            Unreported   \n",
       "5   [Clinically significant exacerbation was defined as worsening of asthma which requires use of sy...   \n",
       "6   [SGRQ consisted of 50 questions (scored from 0 to 100 where 0 indicates best and 100 indicates w...   \n",
       "7                                                                                            Unreported   \n",
       "8   [An adverse event is any untoward medical occurrence, regardless of whether it has a causal rela...   \n",
       "9                                                                                            Unreported   \n",
       "10                                                                                           Unreported   \n",
       "11                                                                                           Unreported   \n",
       "12  [During the clinic visits the Investigator or designee evaluated if the participants were able t...   \n",
       "13  [Due to differences in the labelling requirements among regulatory authorities around the world,...   \n",
       "14  [FEV1 is a standard measurement of air movement in the lungs of patients with asthma. It is the ...   \n",
       "15                                                                                           Unreported   \n",
       "16  [Exacerbations are defined as the worsening of asthma which requires use of systemic corticoster...   \n",
       "17  [Percentage of participants who experienced >=1 HES flare during the 32-Week treatment period or...   \n",
       "18                                                                                           Unreported   \n",
       "19                                                                                           Unreported   \n",
       "20                                                                                           Unreported   \n",
       "21  [The average over the mean differences between benralizumab and placebo for change from baseline...   \n",
       "22                                                                                           Unreported   \n",
       "23                                                                                           Unreported   \n",
       "24                                                                                           Unreported   \n",
       "25  [An asthma exacerbation was defined as a worsening of asthma that led to any of the following:\\n...   \n",
       "26                                                                                           Unreported   \n",
       "27  [AEs were collected from the Baseline visit until the follow-up visit (approx. 12 weeks post-las...   \n",
       "28  [Baseline (BL) dose was the prescribed optimized prednisone/prednisolone dose following the OCS ...   \n",
       "29                                                                                           Unreported   \n",
       "30                                                                                           Unreported   \n",
       "31                                                                                           Unreported   \n",
       "32                                                                                           Unreported   \n",
       "\n",
       "                                                                                OutcomeMeasureTimeFrame  \\\n",
       "0   [Day 1 to Month 12, Day 1 (baseline, pre-dose), Week 16, Day 1 (baseline, pre-dose), Weeks 4, 8,...   \n",
       "1   [Day 1 to Week 52, Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose)...   \n",
       "2   [Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16, Day 1 (baseline, pre-dose), Weeks 4, 8, 12, ...   \n",
       "3   [Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observa...   \n",
       "4                                                                                            Unreported   \n",
       "5   [Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 and 52, Baseline and Weeks 12, 24, 36 an...   \n",
       "6   [Baseline and Week 24, Baseline and Week 24, Baseline (Visit 2-latest pre-dose assessment) and W...   \n",
       "7                                                                                            Unreported   \n",
       "8   [Day 1 to up to Day 269; for participants who discontinued early for reasons other than study te...   \n",
       "9                                                                                            Unreported   \n",
       "10                                                                                           Unreported   \n",
       "11                                                                                           Unreported   \n",
       "12                                                                                     [Week 8, Week 4]   \n",
       "13                                                                     [Week 8, Week 8, Week 4, Week 4]   \n",
       "14  [Baseline (Day 1), Week 16, Baseline (Day 1), Weeks 4, 8, 12, 16, Baseline (Day 1), Weeks 4, 8, ...   \n",
       "15                                                                                           Unreported   \n",
       "16  [Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 172, Baseline (Week 0) to Week 168, Ba...   \n",
       "17  [Up to Week 32, Week 20 to Week 32, Weeks 4, 8, 12, 16, 20, 24, 28 and 32, Up to Week 32, Baseli...   \n",
       "18                                                                                           Unreported   \n",
       "19                                                                                           Unreported   \n",
       "20                                                                                           Unreported   \n",
       "21  [From first IP dose to Day 84, From first IP dose to Day 84, From first IP dose to Day 84, From ...   \n",
       "22                                                                                           Unreported   \n",
       "23                                                                                           Unreported   \n",
       "24                                                                                           Unreported   \n",
       "25  [Baseline (Week 0) up to Week 24, Baseline (Week 0) and Week 24, Baseline (Week 0) and Week 24, ...   \n",
       "26                                                                                           Unreported   \n",
       "27  [From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-l...   \n",
       "28  [Baseline; Weeks 20 to 24, Baseline; Weeks 20 to 24, Weeks 20 to 24, Weeks 20 to 24, Baseline; W...   \n",
       "29                                                                                           Unreported   \n",
       "30                                                                                           Unreported   \n",
       "31                                                                                           Unreported   \n",
       "32                                                                                           Unreported   \n",
       "\n",
       "                                                                                OutcomeMeasurementValue  \\\n",
       "0   [2.115, 0.859, 0.122, 0.223, 0.094, 0.187, 0.777, 0.987, -0.660, -0.857, NA, NA, 0.080, 0.115, -...   \n",
       "1   [1.804, 0.904, 0.110, 0.248, 0.695, 0.933, -0.676, -0.941, 34.9, NA, 0.109, 0.167, -0.36, -0.64,...   \n",
       "2   [0.126, 0.242, 0.286, 0.172, 0.220, 0.301, -0.145, -0.114, 0.089, 0.8, 4.9, 7.5, 0.8, 5.5, 6.7, ...   \n",
       "3   [359, 385, 744, 31, 47, 78, 49, 41, 90, 6, 12, 18, 33, 45, 78, 1, 2, 3, 344, 367, 711, 78, 82, 1...   \n",
       "4                                                                                            Unreported   \n",
       "5   [31.8, 20.2, 49.3, 32.3, 56.0, 40.3, 60.7, 47.1, 6.03, 1.16, 6.58, 1.03, 6.48, 1.20, 6.17, 1.00,...   \n",
       "6                                                          [-7.9, -15.6, 56, 176, 55, 73, -0.40, -0.80]   \n",
       "7                                                                                            Unreported   \n",
       "8   [102, 114, 7, 6, 5, 11, 0, 0, 2, 0, 0, 0, 8, 5, 1, 0, 4, 2, 2, 0, 0, 1, 2, 0, 1, 1, 0, 1, 12, 10...   \n",
       "9                                                                                            Unreported   \n",
       "10                                                                                           Unreported   \n",
       "11                                                                                           Unreported   \n",
       "12                                                                                           [100, 100]   \n",
       "13                                                                                     [99, 98, 98, 96]   \n",
       "14  [-0.2778, 0.0229, 0.175, 0.251, -0.614, -0.737, -0.2944, 0.0271, 0.164, 0.224, 0.199, 0.249, 0.1...   \n",
       "15                                                                                           Unreported   \n",
       "16  [0.93, 315, 84, -0.16, -0.15, -0.21, -0.17, -0.18, -0.08, -0.03, -0.12, -0.06, -0.01, -0.09, 0.3...   \n",
       "17  [56, 28, 35, 17, 7.4, 5.6, 14.9, 7.4, 26.2, 9.3, 33.8, 13.0, 41.3, 13.0, 48.9, 14.8, 50.8, 20.5,...   \n",
       "18                                                                                           Unreported   \n",
       "19                                                                                           Unreported   \n",
       "20                                                                                           Unreported   \n",
       "21  [0.21, 0.132, 0.22, 0.203, 0.209, 0.149, -0.415, -0.208, -88.55, 11.55, 0.104, 0.081, 0.125, 0.0...   \n",
       "22                                                                                           Unreported   \n",
       "23                                                                                           Unreported   \n",
       "24                                                                                           Unreported   \n",
       "25  [0.94, 1.86, -23.06, -14.94, 0.30, 0.14, -1.47, -1.01, 123, 107, 27.17, 7.06, 16.47, -6.61, 17.7...   \n",
       "26                                                                                           Unreported   \n",
       "27  [558, 119, 94, 1, 0, 31, 615, 0, 31, 0.93, -0.09, -0.11, -0.05, -0.10, -0.09, 0.20, 67, 50, 29, ...   \n",
       "28       [7, 16, 5, 12, 10, 9, 7, 7, 37, 25, 22, 37, 44, 32, 21, 37, 45, 32, 5, 10, 61, 59, 0.0, -50.0]   \n",
       "29                                                                                           Unreported   \n",
       "30                                                                                           Unreported   \n",
       "31                                                                                           Unreported   \n",
       "32                                                                                           Unreported   \n",
       "\n",
       "                                                                            OutcomeMeasureUnitOfMeasure  \n",
       "0   [CAEs in 52 weeks, liters, liters, units on a scale, units on a scale, weeks, units on a scale, ...  \n",
       "1   [CAEs in 52 weeks, liters, units on a scale, units on a scale, weeks, units on a scale, puffs/da...  \n",
       "2   [liters, liters, liters/second, percentage of predicted FEV1, units on a scale, units on a scale...  \n",
       "3   [participants, participants, liters, percentage of predicted FEV1, liters, liters/second, # puff...  \n",
       "4                                                                                            Unreported  \n",
       "5           [Percentage of participants, Ratio, Percentage of participants, Percentage of participants]  \n",
       "6                  [Scores on a scale, Milliliters (mL), Percentage of participants, Scores on a scale]  \n",
       "7                                                                                            Unreported  \n",
       "8   [Participants, Participants, Participants, Participants, Participants, CAEs / year, CAEs / year,...  \n",
       "9                                                                                            Unreported  \n",
       "10                                                                                           Unreported  \n",
       "11                                                                                           Unreported  \n",
       "12                                             [Percentage of participants, Percentage of participants]  \n",
       "13  [Percentage of participants, Percentage of Participants, Percentage of participants, Percentage ...  \n",
       "14  [FEV1 liters/ eosinophils 10^9/liter, liters, units on a scale, FEV1 liters/ eosinophils 10^9/li...  \n",
       "15                                                                                           Unreported  \n",
       "16  [Exacerbations per year, Participants, Scores on a scale, Milliliter, Participants, Participants...  \n",
       "17  [Percentage of participants, Percentage of participants, Probability expressed as percentage, Fl...  \n",
       "18                                                                                           Unreported  \n",
       "19                                                                                           Unreported  \n",
       "20                                                                                           Unreported  \n",
       "21  [Liter, Liter, Percent change, Liter, Liter, Percentage of Participants, Score on a scale, Score...  \n",
       "22                                                                                           Unreported  \n",
       "23                                                                                           Unreported  \n",
       "24                                                                                           Unreported  \n",
       "25  [Events/year, Scores on a scale, Liters (L), Scores on a scale, Participants, L/minute, Scores o...  \n",
       "26                                                                                           Unreported  \n",
       "27  [Participants, Participants, Exacerbations per year, Score on scale, Milliliters (mL), Participa...  \n",
       "28           [Participants, Participants, Participants, Participants, Percentage reduction in OCS dose]  \n",
       "29                                                                                           Unreported  \n",
       "30                                                                                           Unreported  \n",
       "31                                                                                           Unreported  \n",
       "32                                                                                           Unreported  "
      ]
     },
     "execution_count": 79,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "study_table"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
